Clinical Trial

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Name: A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia — clinical trial record (NCT07134088)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.

Protocol Amendment History 1 change

critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-16

Trial Details

NCT Number	NCT07134088
Lead Sponsor	Amgen Collaborators: BeOne Medicines
Conditions	Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Enrollment	104 participants
Start Date	2025-12-08
Primary Completion	2028-12-05 (estimated)
Study Completion	2030-06-18 (estimated)
Updated on ClinicalTrials.gov	2026-05-15